Transcat/$TRNS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Transcat
Transcat Inc is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing services and products to high regulated industries, particularly the life sciences industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. It conducts business through two operating segments: Services and Distribution.
- Ticker
- $TRNS
- Sector
- Industrials
- Primary listing
- NASDAQ
- Employees
- 1,413
- Headquarters
- Rochester, United States
- Website
- www.transcat.com
Transcat Metrics
BasicAdvanced
$767M
227.40
$0.36
0.67
-
Price and volume
Market cap
$767M
Beta
0.67
52-week high
$100.00
52-week low
$50.23
Average daily volume
130K
Financial strength
Current ratio
2.492
Quick ratio
1.931
Long term debt to equity
0.458
Total debt to equity
0.458
Interest coverage (TTM)
2.73%
Profitability
EBITDA (TTM)
42.984
Gross margin (TTM)
32.50%
Net profit margin (TTM)
0.99%
Operating margin (TTM)
4.43%
Effective tax rate (TTM)
38.56%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
2.18%
Return on equity (TTM)
1.16%
Valuation
Price to earnings (TTM)
227.401
Price to revenue (TTM)
2.197
Price to book
2.53
Price to tangible book (TTM)
-364.58
Price to free cash flow (TTM)
30.178
Free cash flow yield (TTM)
3.31%
Free cash flow per share (TTM)
2.715
Growth
Revenue change (TTM)
20.91%
Earnings per share change (TTM)
-74.99%
3-year revenue growth (CAGR)
13.78%
10-year revenue growth (CAGR)
10.74%
3-year earnings per share growth (CAGR)
-36.10%
10-year earnings per share growth (CAGR)
-5.44%
What the Analysts think about Transcat
Analyst ratings (Buy, Hold, Sell) for Transcat stock.
Analyst projections of the future price of Transcat stock.
Bulls say / Bears say
In the latest reported quarter, organic Service revenue rose 12.8%, while Service gross margin expanded by 90 basis points. That points to strong underlying demand and improving delivery economics, not just growth from acquisitions. (SEC)
Calibration work is recurring and supports customers in regulated industries where measurement failures carry high costs. Transcat said Service revenue had grown year on year for 68 consecutive quarters, and life sciences makes up about 60% of that segment. (Transcat)
The Southeastern Biomedical acquisition expands Transcat’s healthcare calibration and maintenance services across the south-eastern US. It adds capabilities and reach in a market the company expects to grow. (Transcat)
Despite revenue growth, fiscal 2026 operating income fell 25.8% and net income fell 63% year on year. The gap between strong sales growth and weaker reported earnings highlights the risk that acquisition, staffing and other costs will continue to absorb the gains. (SEC)
Debt rose to $110.4 million by June 2026, from $99.9 million at the fiscal year end, with borrowings partly funding acquisitions. That increases interest and repayment exposure if growth or integration falls short. (SEC)
A recent valuation analysis put the shares at 43.8 times forward earnings, a demanding multiple that leaves less room for slower growth or weaker execution. Even a strong business may disappoint investors if its earnings do not catch up with the share price. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 21 Oct 2026.
Transcat Financial Performance
Revenues and expenses
Transcat Earnings Performance
Company profitability
Upcoming events
No upcoming events
Transcat News
AllArticlesVideos
Transcat to Host Second Quarter Fiscal Year 2027 Conference Call and Webcast on Tuesday, November 3, 2026 at 4:30 p.m. Eastern Time
Business Wire4 days ago
Transcat Expands its Biomedical Calibration Channel with the Acquisition of Southeastern Biomedical
Business Wire2 months ago
Transcat to Participate in Jefferies, Lake Street and D.A. Davidson Investor Conferences in September
Business Wire2 months ago
Funds containing Transcat
Fund name | Fund size | $TRNS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.03% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.01% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.01% |
iShares MSCI World Small Cap£WLDS | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.